iOmx is currently generating a pipeline of drug candidates against six of its proprietary immune-oncology targets. iOmx has uncovered novel modes of action for these newly identified immune-checkpoint targets. The Company plans to establish clinical proof-of-concept for select drug candidates.

Leveraging its systematic approach to identify novel checkpoint modulators directly on tumor samples, iOmx is unveiling organ-specific tumor evasion strategies that will allow developing next-generation targeted cancer immunotherapies. iOmx is excellently positioned to play a leading role in this field.

To learn more about potential partnering opportunities, please contact us at: info@iomx.de